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Abstract
Background Cold ischemia time and the presence of postoperative hepatic arterial thrombosis have been associated with
biliary complications (BC) after liver transplantation. An ABO-incompatible blood group has also been suggested as a
factor for predisposal towards BC. However, the influence of Rh nonidentity has not been studied previously.
Materials Three hundred fifty six liver transplants were performed from 1995 to 2000 at our hospital. BC incidence and risk
factors were studied in 345 patients.
Results Seventy patients (20%) presented BC after liver transplantation. Bile leakage (24/45%) and stenotic anastomosis
(21/30%) were the most frequent complications. Presence of BC in Rh-nonidentical graft–host cases (23/76, 30%) was
higher than in Rh-identical grafts (47/269, 17%) (P=0.01). BC was also more frequent in grafts with arterial thrombosis
(9/25, 36% vs 60/319, 19%; P=0.03) and grafts with cold ischemia time longer than 430 min (26/174, 15% vs 44/
171, 26%; P=0.01). Multivariate logistic regression confirmed that Rh graft–host nonidentical blood groups [RR=2
(1.1–3.6); P=0.02], arterial thrombosis [RR=2.6(1.1–6.4); P=0.02] and cold ischemia time longer than 430 min [RR=1.8
(1–3.2); P=0.02] were risk factors for presenting BC.
Conclusion Liver transplantation using Rh graft–host nonidentical blood groups leads to a greater incidence of BC.
Keywords Livertransplantation.Biliary complications.
Rhnonidentity
Introduction
Biliary complications (BC) after liver transplantation (LT)
are still a significant cause of morbidity and mortality.
1,2
Hepatic arterial thrombosis, long ischemia time, inadequate
exposure of the biliary epithelium to the preservation
solution, and chronic rejection have been associated with
BC.
3–5 However, complications may also occur in the
absence of these pathogenic factors. The expression of
donor ABH antigen in the vascular and biliary epithelium
of hepatic allografts has been linked to higher risk of biliary
and arterial complications, especially in ABO-incompatible
grafts.
6 However, the influence of Rh nonidentity in LT has
not been analyzed until now.
J Gastrointest Surg (2007) 11:458–463
DOI 10.1007/s11605-007-0116-0
J. Busquets:J. Torras:J. Fabregat: E. Ramos:
L. Llado: A. Rafecas
Department of Surgery, Hospital Universitari de Bellvitge,
Barcelona, Spain
J. Castellote
Department of Gastroenterology, Hospital Universitari de
Bellvitge, Barcelona, Spain
E. de la Banda
Department of Haematology, Hospital Universitari de Bellvitge,
Barcelona, Spain
J. Figueras
Department of Surgery, Hospital Josep Trueta,
Girona, Spain
J. Busquets (*)
Hospital Universitari de Bellvitge,
c/ Feixa Llarga s.n.,
08907 Barcelona, Spain
e-mail: jbusquets@csub.scs.esThe aim of this study is to analyze the incidence of BC
after LT, to define their etiological risk factors, and to study
the influence of Rh nonidentity on presentation of BC after
LT.
Materials
Three hundred and fifty-six (n=356) liver transplants were
performed at our hospital between January 1995 and
November 2000. Eleven were excluded from the study
because important data were missing (n=345). The study
was closed on May 2001 with a 6-month-minimum graft
follow-up. The procurement procedure was based on the
rapid flush technique.
7 After reperfusion of the allograft,
cholecystectomy was performed, the donor bile duct being
divided just above the cystic duct junction in most cases.
Biliary anastomosis was performed with interrupted
stitches of 6-0 Polydioxanone suture Ethicon® (Johnson
& Johnson, Brussels, Belgium). The biliary reconstruction
technique was end-to-end anastomosis in the majority of
LTs (315 patients, 91%). T-tubes were used in four
patients due to diameter discrepancy between the biliary
ducts of the donor and the recipient. If the primary disease
affected the biliary tract, or if technical factors made end-
to-end anastomosis difficult, Roux-en-Y-hepaticojejunos-
tomy was performed (25 out of 345, 7%). The outcome
was assessed in terms of biliary and arterial complications
and patient status (alive, retransplanted, or dead). BCs
were studied routinely with abdominal ultrasonography at
day 1 post LT, weekly before discharge from hospital and
monthly thereafter or when there was clinical or biochemical
suspicion of BC, and this was confirmed with magnetic
resonance cholangiography, percutaneous transhepatic chol-
angiography, or endoscopic retrograde cholangio-pancrea-
tography when necessary. The immunosuppressive regimen
was based on quadruple sequential therapy with antilym-
phocyte globulin, Sandimmune Neoral® (Novartis, Basel,
Switzerland), steroids, and azathioprine in most patients, as
reported elsewhere.
8 Cellular rejection was diagnosed
according to histological criteria.
9
Statistical analysis Chi-squared analysis was used to
compare dichotomous variables and the presence of BC.
Variables that were statistically significant in the univariate
analysis were introduced in a multivariate logistic regres-
sion analysis. Other known risk factors for developing BC
were introduced into the model as covariates: donor age,
acute rejection, and chronic rejection. Variables with P>
0.05 were excluded from the final equation. Kaplan–Meier
estimates of the rate of BC for both groups and the results
were compared with a log-rank test.
Results
Perioperative data and surgical details The preservation
solutions used were the University of Wisconsin solution in
332 (97%), Celsior solution in 5 (1%), and histidine-
tryptophan-ketoglutarate solution in 8 (2%). Twenty grafts
(6%) were shipped by another team. The study of donor
risk factors demonstrated that there was no hemodynamic
instability (systolic pressure lower than 60 mmHg for more
than 1 h) in 265 cases (77%), and that the main cause of
death was traumatic head injury (129/36%). Donor Rh
blood group was positive in 301 (87%) and negative in 44
cases (13%). Recipient Rh blood group was positive in 284
(82%) patients, and negative in 61 (18%). Rh blood groups
of donor and recipient were positive to positive in 255 cases
(74%), positive to negative in 46 (13%), negative to
positive in 30 (9%), and negative to negative in 14 (4%).
Donors and recipients had identical Rh in 269 cases (78%)
and nonidentical in 76 (22%). The donor ABO blood group
was A in 157 (46%), B in 29 (8%), AB in 19 (5%), and O
in 140 (41%), while recipients were A in 161 cases (46%),
B in 34 (10%), AB in 20 (6%) and O in 130 (38%). The
ABO groups of transplanted grafts and hosts were identical
in 97% of cases (335 patients) and compatible in 10 cases.
There were no cases of incompatible grafts.
During postoperative development, 25 LTs presented
arterial thrombosis (7%). Eight grafts presented primary
nonfunction and were retransplantated (2.2%), and 43
presented initial poor function that recovered spontaneously
(12%).
3 Biopsy-proven acute rejection was diagnosed in 66
grafts (19%) after transplantation, with development to
chronic ductopenic rejection in 8 (2%).
BCs and Rh mismatch BCs appeared in 70 of the 345
patients (20%). Cross-tabs were built to analyze differences
between the grafts that suffered BCs and the rest. Both
groups were similar in terms of donor preoperative
evaluation and support, recipient descriptive data, and
surgical terms. The incidence of BC in nonidentical Rh
graft–host cases (23/76; 30%) was significantly higher than
in cases of identical Rh graft–host (47/269; 17%, P=0.01).
Cases of arterial thrombosis after LTs and ischemia time
longer than 430 min were also associated with a higher
incidence of BC (Table 1).
Multivariate Analysis of Risk Factors for BCs
In multivariate analysis, arterial thrombosis presented an
adjusted relative risk (aRR)=2.6, CI 95%=(1.1–6.4) (P=
0.02), cold ischemia time aRR=1.8 (CI 95% =1–3.2)
(P=0.02), and Rh graft–host nonidentity aRR=2 (CI 95%=
1.1–3) (P=0.02) were confirmed as independent risk
factors for BC. Other variables included in the initial
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estimator and log-rank test confirmed these findings (P=
0.01, Fig. 1). To discard the possible association between
the Rh match and the two other risk factors, we
demonstrated that arterial thrombosis had similar incidence
in Rh-nonidentical grafts (3/75, 4%) and in Rh-identical
grafts (22/269, 8%; P=0.1). Moreover, grafts with long
ischemia times (>430 min) had similar incidence in the Rh-
nonidentical (42/76, 55%) group and in Rh-identical
patients (129/269, 48%; P=0.1).
Type and Management of BCs
BCs were diagnosed in 70 patients. Biliary duct anastomo-
sis stricture was the main complication, presented clinically,
Table 1 Demographics and Major Complications Occurring in Both
Groups Studied, Chi-square Test
BCs (n=70) No BCs
(n=275)
Chi-square
Donor data
ABO blood group 0.2
A 25/157
(16%)
132/157
(84%)
B 6/29 (21%) 23/29(79%)
AB 6/19 (32%) 13/19(68%)
O 33/140
(24%)
107/140
(76%)
Rh blood group 0.4
Positive 59/301
(19%)
242/301
(81%)
Negative 11/44 (25%) 33/44 (75%)
Sex 0.4
Male 51/233
(22%)
182/233
(75%)
Female 19/110 (17%) 91/110 (83%)
Donor age 0.4
≤70 years 66/320
(20%)
254/320
(80%)
>70 years 4/25 (16%) 21/25 (84%)
Recipient data
Rh blood group 0.2
Positive 54/284
(19%)
230/284
(81%)
Negative 16/61 (26%) 45/61 (74%)
Rh D-R crossing 0.1
Positive–positive 45/255
(18%)
210/255
(82%)
Positive–negative 14/46 (30%) 32/46 (70%)
Negative–positive 9/30 (30%) 21/30 (70%)
Negative–negative 2/14 (14%) 12/14 (86%)
Rh D-R identity 0.01
Identical 47/269
(17%)
222/269
(83%)
Nonidentical 23/76 (30%) 53/76 (70%)
ABO blood group 0.4
A 27/161
(17%)
134/161
(83%)
B 7/34 (20%) 27/34(80%)
O 30/130
(23%)
100/130(77%)
AB 6/20 (30%) 14/20 (70%)
ABO D-R identity 0.4
Identical 67/335
(20%)
268/335
(80%)
Nonidentical 3/10 (30%) 7/10 (70%)
Sex of recipient 0.4
Male 48/214(22%) 166/214
(78%)
Female 22/130(17%) 108/130(83%)
Recipient age 0.2
<60 years 41/221
(18%)
180/221
(82%)
≥60 years 29/124
(24%)
95/124 (76%)
Table 1 (continued)
BCs (n=70) No BCs
(n=275)
Chi-square
Diagnosis 0.3
Choleostasis 2/14(15%) 12/14(85%)
Cirrhosis 32/162
(20%)
130/162(80%)
Hepatocarcinoma 27/103(26%) 76/103(74%)
Other etiology 1/18(5%) 17/18(95%)
Re-OLT 7/39(18%) 32/39 (89%)
Other tumors 1/9(11%) 8/9 (89%)
Surgical data
Cold ischemic time 0.01
≤430 min 26/178
(15%)
148/178
(85%)
>430 min 44/171
(26%)
127/171
(74%)
Type of anastomosis 0.6
Termino-terminal 64/315(20%) 251/315(80%)
Graft evolution data
Arterial thrombosis 0.03
Yes 9/25 (36%) 16/25(64%)
No 60/319
(19%)
259/319(81%)
Initial poor function 0.6
Yes 10/43 (23%) 33/43 (77%)
No 60/302
(20%)
242/302
(80%)
Primary nonfunction 0.1
Yes 0 8/8 (100%)
No 70/336
(20%)
266/336
(80%)
Acute rejection 0.4
Yes 11/66(17%) 55/66(83%)
No 59/279(21%) 220/279(79%)
Chronic rejection 0.5
Yes 1/8(12%) 7/8(88%)
No 69/337 (20%) 268/337(80%)
OLT orthotopic liver transplantation
460 J Gastrointest Surg (2007) 11:458–463with (7/10%) or without postoperative leak (21/30%).
Solitary leaks (17/24%), ischemic-type BCs (ITBC) with
arterial thrombosis (6/9%), ITBC without arterial thrombo-
sis (10/14%), and lithiasis (9/13%) were also related
complications. The therapeutic approach was surgical in
23 patients (33%), endoscopic in 20 (28%), retransplanta-
tion in 11 (16%), and conservative treatment in 16 (23%).
Chi-square test was performed to analyze differences
between the type of BC and the three risk factors found. As
would be expected, arterial thrombosis was identified in all
the cases of ITBC with thrombosis, in a higher percentage
than the other BCs (P<0.001). However, the different types
of BCs were not associated with long ischemia time (P=0.2)
or Rh-identity (P=0.4).
Finally, chi-square test was also performed to analyze
differences among the three BC risk factors and medical
management. The therapeutic approach regarding Rh-mis-
match was similar in both groups (P=0.3). Retransplantation
was a frequent approach in arterial thrombosis management
(4/9, 40%; P=0.04). Interestingly, when the BC was
presented in grafts with short ischemic time (<430 min),
management by surgery (10/26, 38%) or an endoscopic
approach (10/26, 38%) were sufficient, and it was not
necessary to retransplant. However, when the BC arose in a
graft with a long ischemic time (>430 min) the management
Table 2 Biliary Complications
Univariate logistic
regression
Multivariate
logistic regression
Donor age >70 years 0.5 0.7
Rh D-R identity
identical nonidentical
0.01; 2(1.1–3.6) 0.02; 2 (1.1–3.6)
Cold ischemic time
>430 min
0.01; 1.9(1.1–3.3) 0.02; 1.8(1–3.2)
Arterial thrombosis
(yes)
0.04; 2.4(1–5.7) 0.02; 2.6 (1.1–6.4)
Acute rejection (yes) 0.4 0.4
Chronic rejection (yes) 0.5 0.5
Univariate and multivariate logistic regression.
Rh graft-host non-identical blood group (23/76, 30%)  
Rh graft-host identical blood group  (47/269, 17%) 
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Figure 1 Kaplan–Meier esti-
mates for the onset of BCs for
nonidentical Rh graft–host (P=
0.01).
J Gastrointest Surg (2007) 11:458–463 461was more aggressive, with 29% of patients (13/44) needing
surgery and 25% (11/44) needing retransplantation.
Discussion
Etiopathogenesis of BC
Currently, orthotopic liver transplants are performed with
good results at several centers without taking the donor–
recipient Rh relationship into account. In fact, no prior
work has shown greater morbidity or mortality after the
usage of Rh-incompatible liver grafts. However, it was in
studying the causes of BC in our grafts in prior studies that
we began to suspect the existence of a possible relationship
between BC and Rh incompatibility. First, we observed a
greater rate of BC in the presence of preservation lesions in
postreperfusion biopsies.
10 Thus, we found that the biliary
epithelium is very sensitive to changes during preservation.
Second, the description of lesions like ITBC,
11 to which
surgical technique does not contribute as a primary cause,
led us to suspect possible immunological pathogenesis of
the BC. Lastly, it is paradoxical to find that, while surgical
technique is improving and satisfactory results are achieved
in liver transplants, BCs are still a problem, leading us to
suspect that there are unidentified factors that cause them.
The arterial thrombosis and long cold ischemia time were
independent risk factors for developing BC, as was
expected and reported by others.
11,12 In our study we have
demonstrated that even though BC in grafts with short
ischemia can be resolved with surgery or endoscopy, the
prognosis of BC was worse in cases of long ischemic grafts
requiring retransplantation.
Relationship Between ABO and Rh in Liver Transplants
As for the donor–recipient ABO relationship, the usage of
ABO-incompatible grafts has been discouraged due to the
high rate of BC and poor graft survival.
6,13,14 In the
Sanchez-Urdazpal study,
6 82% of the 18 ABO-incompati-
ble grafts presented BC in comparison with 6% of the
control group, while Farges,
14 published slightly better
results several years later with BC of 54%. Therefore, these
grafts are used in extremely urgent cases when there is no
other possible alternative. Immunological phenomena, such
as rejection,
3 may also lead to biliary strictures. In the same
way, the ABO system was shown to cause more BC and
worse graft survival in LT.
6,13–15 However, Rh nonidentity
seems to have better tolerance and is not a cause of graft
refusal when a donor appears. Surprisingly, our study
demonstrated a higher incidence of BC in the Rh-
nonidentical group.
Some authors
16,17 reported low rates of alloimmuniza-
tion in Rh-negative recipients of Rh-incompatible transfu-
sion after LT. It was suspected that immunosuppressant
drugs modified the immunosuppressive response.
16 How-
ever, debate still exists as to whether the D barrier can be
crossed in LT. Previous studies of ABO barrier and BC
suggested the hypothesis of an immunological injury to the
bile duct epithelium, and the expression of ABH antigens in
the donor 150 days after transplantation.
6 However, the D
antigen is only expressed in erythrocytes.
The nonidentical Rh group has two mismatch possibili-
ties: positive donor to a negative recipient or negative donor
to positive recipient. In the first case (positive to negative)
the immunologic mechanism is easy to understand because
the humoral anti-D (Rh) response may be responsible for the
graft injury.
The other subgroup (negative to positive) may have a
different pathogenic explanation. Bryan et al.
17 hypothe-
sized that two mechanisms could be involved in the same
process in kidney transplantation: other Rh antigenic loci
(C and E) and histocompatibility antigenic crossings. A
negative liver graft in a positive recipient with lymphatic
cells and tissues predisposes to cellular response against it.
Finally, the biliary tract can probably suffer immunological
damage, and thus further BC. Therefore, while the results
of the study lead to suspicion of an immunological
pathogenesis, the mechanism is still unclear.
In conclusion, Rh-nonidentical LT involves a higher rate
of BCs. Future studies should examine the influence of Rh
donor and blood group on graft development. Finally, our
results suggest that there is a summation effect of BC risk
factors. In our opinion, Rh-nonidentical liver grafts should
not undergo a very long ischemia time.
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